Version May 2024
| Availability | Brand (trade) name | Dose | Content per inhalation capsule or MDI puff: Glycopyrrolate (glycopyrronium) base | Content per inhalation capsule or MDI puff: Glycopyrrolate (glycopyrronium) bromide salt | Drug delivered from mouthpiece: Glycopyrrolate (glycopyrronium) base | Drug delivered from mouthpiece: Glycopyrrolate (glycopyrronium) bromide salt |
| Single agent dry powder inhalers (DPI) | ||||||
| Canada and Europe | Seebri Breezhaler | 1 inhalation once daily | 50 mcg glycopyrronium base (labeling within Canada) | 63 mcg glycopyrronium bromide | 44 mcg glycopyrronium base (labeling within European Union) | 55 mcg glycopyrronium bromide |
| Combination long-acting antimuscarinic (LAMA) and long-acting beta2 agonist (LABA) DPI | ||||||
| United States | Utibron Neohaler¶ | 1 inhalation twice daily | 12.5 mcg glycopyrrolate base and 27.5 mcg indacaterol | 15.6 mcg glycopyrrolate bromide and 27.5 mcg indacaterol (labeling within United States) | 10.2 mcg glycopyrrolate base and 20.8 mcg indacaterol | 12.8 mcg glycopyrrolate bromide and 20.8 mcg indacaterol |
| Canada and Europe | Ultibro Breezhaler | 1 inhalation once daily | 50 mcg glycopyrronium base and 110 mcg indacaterol (labeling within Canada) | 63 mcg glycopyrronium bromide and 110 mcg indacaterol | 43 mcg glycopyrronium base and 85 mcg indacaterol (labeling within European Union) | 54 mcg glycopyrronium bromide and 85 mcg indacaterol |
| Combination LAMA and LABA metered dose inhaler (MDI) | ||||||
| United States, Canada, and Europe | Bevespi AerosphereΔ | 2 puffs twice daily | 8.3 mcg glycopyrronium base and 5.8 mcg formoterol fumarate dihydrate per puff released from valve (labeling within Canada) | 10.4 mcg glycopyrrolate bromide and 5.5 mcg formoterol fumarate per puff released from valve | 7.2 mcg glycopyrronium base and 5 mcg formoterol fumarate dihydrate per puff delivered from mouthpiece (labeling within European Union) | 9 mcg glycopyrrolate bromide and 4.8 mcg formoterol fumarate per puff delivered from mouthpiece (labeling within United States) |
| Combination LAMA, LABA, and inhaled corticosteroid (ICS) DPI | ||||||
| Canada and Europe | Enerzair Breezhaler | 1 inhalation once daily | 50 mcg glycopyrronium base, 150 mcg indacaterol, and 160 mcg mometasone (labeling within Canada) | 63 mcg glycopyrronium bromide, 150 mcg indacaterol, and 160 mcg mometasone | 46 mcg glycopyrronium base, 114 mcg indacaterol, and 136 mcg mometasone (labeling within Europe) | 58 mcg glycopyrronium bromide, 114 mcg indacaterol, and 136 mcg mometasone |
| Combination LAMA, LABA, and ICS MDI | ||||||
| United States, Canada, and Europe | Breztri Aerosphere (United States and Canada), Trixeo Aerosphere (Europe) | 2 puffs twice daily | 8.2 mcg glycopyrrolate base, 4.7 mcg formoterol fumarate dihydrate, and 182 mcg budesonide per puff released from valve (labeling within Canada) | 10.4 mcg glycopyrrolate bromide, 5.5 mcg formoterol fumarate, and 182 mcg of budesonide per puff released from valve | 7.2 mcg glycopyrrolate base, 5 mcg formoterol fumarate dihydrate, and 160 mcg budesonide per puff delivered from mouthpiece (labeling within Europe) | 9 mcg glycopyrrolate bromide, 4.8 mcg formoterol fumarate, and 160 mcg budesonide per puff delivered from mouthpiece (labeling within United States) |
NA: not applicable.
* Labeling detail shown according to approved product information within the countries of Europe, Canada, and United States. Labeling conventions may vary in other countries. For additional detail, refer to the Lexicomp drug monographs included within UpToDate and locally approved product information.
¶ Product is no longer available in the United States but may be available elsewhere.
Δ Formoterol content of Bevespi Aerosphere is expressed as formoterol fumarate in the United States and as formoterol fumarate dihydrate in Canada and Europe.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
